Vikas Bhat
Overview
Explore the profile of Vikas Bhat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez M, Wendt D, Lawrence R, Gong K, Ong H, Yip B, et al.
PLoS One
. 2025 Jan;
20(1):e0315005.
PMID: 39752451
The GM2 gangliosidoses, Tay-Sachs disease and Sandhoff disease, are devastating neurodegenerative disorders caused by β-hexosaminidase A (HexA) deficiency. In the Sandhoff disease mouse model, rescue potential was severely reduced when...
2.
He A, Wilkins B, Lan N, Othman F, Sehly A, Bhat V, et al.
J Cardiovasc Comput Tomogr
. 2024 May;
18(4):319-326.
PMID: 38782668
Transcatheter aortic valve replacement (TAVR) is performed to treat aortic stenosis and is increasingly being utilised in the low-to-intermediate-risk population. Currently, attention has shifted towards long-term outcomes, complications and lifelong...
3.
Gahungu N, Lan N, Gamalath S, Phan J, Bhat V, Spencer R, et al.
Intern Med J
. 2024 Mar;
54(8):1320-1328.
PMID: 38506546
Background And Aims: Telehealth plays an integral part in healthcare delivery. The impact of telehealth and the COVID-19 pandemic on medication prescribing and patient satisfaction with telehealth in cardiology clinics...
4.
Abed A, Law N, Calapre L, Lo J, Bhat V, Bowyer S, et al.
Eur J Cancer
. 2022 Jun;
172:98-106.
PMID: 35759816
Introduction: Biomarkers that predict the risk of immune-mediated adverse events (irAEs) among patients with non-small cell lung cancer (NSCLC) may reduce morbidity and mortality associated with these treatments. Methods: We...
5.
von Drygalski A, Bhat V, Gale A, Averell P, Cramer T, Elias D, et al.
Blood Adv
. 2020 Aug;
4(15):3716-3727.
PMID: 32777068
Control of bleeding with direct-acting oral anticoagulants (DOACs) remains an unmet clinical need. Activated superFactor V (superFVa) is an engineered activated protein C (APC)-resistant FVa variant with enhanced procoagulant activity...
6.
Cooke E, Zhou J, Wyseure T, Joshi S, Bhat V, Durden D, et al.
Thromb Haemost
. 2018 Aug;
119(9):1546.
PMID: 30071568
No abstract available.
7.
Cooke E, Zhou J, Wyseure T, Joshi S, Bhat V, Durden D, et al.
Thromb Haemost
. 2018 May;
118(6):1036-1047.
PMID: 29847841
Vascular remodelling is a prominent feature of haemophilic arthropathy (HA) that may underlie re-bleeding, yet the nature of vascular changes and underlying mechanisms remain largely unknown. Here, we aimed to...
8.
Gale A, Bhat V, Pellequer J, Griffin J, Mosnier L, von Drygalski A
Pharm Res
. 2016 Mar;
33(6):1517-26.
PMID: 26960296
Purpose: Activated (super)Factor V ((super)FVa) is a novel engineered FV with excellent prohemostatic efficacy. (Super)FVa has three APC cleavage site mutations and an interdomain disulfide bond. Stability, pharmacokinetics, and immunogenic...
9.
Bhat V, von Drygalski A, Gale A, Griffin J, Mosnier L
Thromb Haemost
. 2015 Oct;
115(3):551-61.
PMID: 26466980
Bypassing inhibitors in haemophilia patients is limited to activated (a) Factor(F)VII products. We introduced "FVa activity augmentation" as another bypassing strategy and studied effects of an engineered FVa variant designated...
10.
Bhat V, Olmer M, Joshi S, Durden D, Cramer T, Barnes R, et al.
Am J Hematol
. 2015 Aug;
90(11):1027-35.
PMID: 26257191
Hemophilic arthropathy is a debilitating condition that can develop as a consequence of frequent joint bleeding despite adequate clotting factor replacement. The mechanisms leading to repeated spontaneous bleeding are unknown....